TY - JOUR
T1 - Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells
AU - Margolis, Naama
AU - Moalem, Hanna
AU - Meirson, Tomer
AU - Galore-Haskel, Gilli
AU - Markovits, Ettai
AU - Baruch, Erez N.
AU - Vizel, Bella
AU - Yeffet, Avner
AU - Kanterman-Rifman, Julia
AU - Debby, Assaf
AU - Besser, Michal J.
AU - Schachter, Jacob
AU - Markel, Gal
N1 - Publisher Copyright:
©2022 American Association for Cancer Research.
PY - 2022/9
Y1 - 2022/9
N2 - The effect of tumor/T-cell interactions on subsequent immune infiltration is undefined. Here, we report that preexposure of melanoma cells to cognate T cells enhanced the chemotaxis of new T cells in vitro. The effect was HLA class I–restricted and IFNg - dependent, as it was abolished by b2M-knockdown, MHC-blocking antibodies, JAK1 inhibitors, JAK1-silencing and IFNgR1-blocking antibodies. RNA sequencing (RNA-seq) of 73 melanoma metastases showed a significant correlation between the interferon-inducible p150 isoform of adenosine-deaminase-acting-on-RNA-1 (ADAR1) enzyme and immune infiltration. Consistent with this, cocultures of cognate melanoma/T-cell pairs led to IFNg -dependent induction of ADAR1-p150 in the melanoma cells, as visualized in situ using dynamic cell blocks, in ovo using fertilized chick eggs, and in vitro with Western blots. ADAR1 staining and RNA-seq in patient-derived biopsies following immunotherapy showed a rise in ADAR1-p150 expression concurrently with CD8þ cell infiltration and clinical response. Silencing ADAR1-p150 abolished the IFNg-driven enhanced T-cell migration, confirming its mechanistic role. Silencing and overexpression of the constitutive isoform of ADAR1, ADAR1-p110, decreased and increased T-cell migration, respectively. Chemokine arrays showed that ADAR1 controls the secretion of multiple chemokines from melanoma cells, probably through microRNA-mediated regulation. Chemokine receptor blockade eliminated the IFNg-driven T-cell chemotaxis. We propose that the constitutive ADAR1 downregulation observed in melanoma contributes to immune exclusion, whereas antigen-specific T cells induce ADAR1-p150 by releasing IFNg, which can drive T-cell infiltration.
AB - The effect of tumor/T-cell interactions on subsequent immune infiltration is undefined. Here, we report that preexposure of melanoma cells to cognate T cells enhanced the chemotaxis of new T cells in vitro. The effect was HLA class I–restricted and IFNg - dependent, as it was abolished by b2M-knockdown, MHC-blocking antibodies, JAK1 inhibitors, JAK1-silencing and IFNgR1-blocking antibodies. RNA sequencing (RNA-seq) of 73 melanoma metastases showed a significant correlation between the interferon-inducible p150 isoform of adenosine-deaminase-acting-on-RNA-1 (ADAR1) enzyme and immune infiltration. Consistent with this, cocultures of cognate melanoma/T-cell pairs led to IFNg -dependent induction of ADAR1-p150 in the melanoma cells, as visualized in situ using dynamic cell blocks, in ovo using fertilized chick eggs, and in vitro with Western blots. ADAR1 staining and RNA-seq in patient-derived biopsies following immunotherapy showed a rise in ADAR1-p150 expression concurrently with CD8þ cell infiltration and clinical response. Silencing ADAR1-p150 abolished the IFNg-driven enhanced T-cell migration, confirming its mechanistic role. Silencing and overexpression of the constitutive isoform of ADAR1, ADAR1-p110, decreased and increased T-cell migration, respectively. Chemokine arrays showed that ADAR1 controls the secretion of multiple chemokines from melanoma cells, probably through microRNA-mediated regulation. Chemokine receptor blockade eliminated the IFNg-driven T-cell chemotaxis. We propose that the constitutive ADAR1 downregulation observed in melanoma contributes to immune exclusion, whereas antigen-specific T cells induce ADAR1-p150 by releasing IFNg, which can drive T-cell infiltration.
UR - http://www.scopus.com/inward/record.url?scp=85137139007&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-21-0643
DO - 10.1158/2326-6066.CIR-21-0643
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35731225
AN - SCOPUS:85137139007
SN - 2326-6066
VL - 10
SP - 1127
EP - 1140
JO - Cancer immunology research
JF - Cancer immunology research
IS - 9
ER -